-
| Exchange | NASDAQ |
|---|---|
| CurrencyCode | USD |
| ISIN | USM201561018 |
| Sector | Other |
| Industry | Other |
| PE Ratio | None |
|---|---|
| Target Price | 9 |
| Dividend Yield | 0.0% |
| Beta | nan |
| Market Cap | None |
Bioblast Pharma Ltd., a clinical-stage biotechnology company, focuses on the development of clinically meaningful therapies for patients with rare and ultra-rare genetic diseases. Its product candidate is Trehalose intravenous 90mg/mL solution, a protein stabilizer and autophagy enhancer for the treatment of patients with oculopharyngeal muscular dystrophy and spinocerebellar ataxia type 3. The company has a collaboration with Team Sanfilippo to evaluate Trehalose for the treatment of sanfilippo syndrome. Bioblast Pharma Ltd. was founded in 2012 and is headquartered in Tel Aviv, Israel.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for ORPN using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025